Cineverse Corp. (Cinedigm Corp.) 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, filed on March 21, 2014, covers events occurring on March 19 and March 20, 2014. The registrant, Cinedigm Corp., is a Delaware corporation headquartered in New York. The filing primarily reports the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The financial details contained in this document are limited to the terms of the equity offering:
- Shares Offered: 10,200,000 shares of Class A Common Stock.
- Over-Allotment Option: The underwriter has a 30-day option to purchase up to an additional 1,530,000 shares.
- Underwriter Expenses: The Company agreed to reimburse Piper Jaffray & Co. for up to $150,000 in expenses.
- Offering Price: The specific price per share is not stated in the text of this filing; it is referenced in the attached press release (Exhibit 99.2).
Material Changes
The primary material change is the execution of an Underwriting Agreement with Piper Jaffray & Co. on March 20, 2014. This agreement facilitates a public offering pursuant to a shelf registration statement (Form S-3) declared effective on March 13, 2014. This represents a significant capital raising event for the Company.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard indemnification clauses. The Company agreed to indemnify the Underwriter against certain liabilities, including those under the Securities Act. The full text of the Underwriting Agreement, which contains detailed covenants and representations, is incorporated by reference as Exhibit 1.1.
Investor Verification Checklist
- Verify the final offering price per share and total gross proceeds by reviewing the press release attached as Exhibit 99.2.
- Confirm whether the underwriter exercised the 1,530,000 share over-allotment option within the 30-day window.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants, lock-up periods, and use of proceeds.
- Check subsequent filings to determine the net proceeds received after deducting underwriting discounts and the $150,000 expense reimbursement.